Headlines about Deciphera Pharmaceuticals (NASDAQ:DCPH) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.402311984387 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s analysis:
- Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.33 Consensus Price Target by Brokerages (americanbankingnews.com)
- Deciphera Pharmaceuticals : Announces Third Quarter 2017 Financial Results and Corporate Highlights (4-traders.com)
- Opening Bell, November 15, 2017 (finance.yahoo.com)
- Deciphera Pharmaceuticals, Inc. (DCPH) Posts Quarterly Earnings Results, Misses Expectations By $5.30 EPS (americanbankingnews.com)
- Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights (finance.yahoo.com)
A number of equities analysts recently issued reports on DCPH shares. Nomura started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Piper Jaffray Companies started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock. JMP Securities started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “outperform” rating and a $38.00 target price on the stock. J P Morgan Chase & Co started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Instinet started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $43.40.
Shares of Deciphera Pharmaceuticals (NASDAQ DCPH) traded up $1.83 during trading hours on Friday, reaching $19.60. The company’s stock had a trading volume of 154,003 shares, compared to its average volume of 174,667. Deciphera Pharmaceuticals has a fifty-two week low of $16.11 and a fifty-two week high of $24.50.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($5.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($5.30). equities research analysts anticipate that Deciphera Pharmaceuticals will post -2.13 earnings per share for the current year.
In related news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
ILLEGAL ACTIVITY NOTICE: “Deciphera Pharmaceuticals (DCPH) Getting Somewhat Favorable Press Coverage, Study Finds” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/20/deciphera-pharmaceuticals-dcph-getting-somewhat-favorable-press-coverage-study-finds.html.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.
Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.